+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2024-2030- Product Image
Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2024-2030- Product Image
Sale

Global Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5264367
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiviral Therapeutics Market size was estimated at USD 75.53 billion in 2023, USD 82.01 billion in 2024, and is expected to grow at a CAGR of 8.28% to reach USD 131.82 billion by 2030.

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics.

Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options.

The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

Market Trends by Segment

  • Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza
  • Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
  • Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Gilead Sciences, Inc. and Assembly Biosciences, Inc. announced a comprehensive 12-year strategic partnership. This alliance is set to boost the development of groundbreaking antiviral agents, concentrating on Assembly Bio’s core competencies in combating herpesviruses, hepatitis B (HBV) and hepatitis D virus (HDV).

FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults

The U.S. Food and Drug Administration has officially approved Paxlovid, an oral antiviral regimen consisting of nirmatrelvir and ritonavir tablets specifically designed for at-home administration to treat adult patients with mild-to-moderate COVID-19 who are at an increased risk of developing severe illness, which can lead to hospitalization or even fatality. This authorization marks Paxlovid as the first oral antiviral medication and the fourth therapeutic overall to receive FDA approval for combatting COVID-19 among adults.

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Shionogi & Co., Ltd updated their intensive clinical development initiatives for ensitrelvir, a pioneering oral medication designed to combat COVID-19. Known commercially as Xocova within Japan, ensitrelvir has secured emergency use authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for treating SARS-CoV-2 infections, based on favorable outcomes in the Asia-conducted Phase 3 segment of a combined Phase 2/3 clinical trial involving non-hospitalized subjects. As Shionogi continues to pursue global recognition, numerous Phase 3 clinical trials are being conducted to validate the safety profile and efficacy of ensitrelvir across diverse patient demographics.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.

This research report offers invaluable insights into various crucial aspects of the Antiviral Therapeutics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
5.1.2. Restraints
5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
5.1.3. Opportunities
5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
5.1.3.2. Improved Testing and Analysis of Viral Infections
5.1.4. Challenges
5.1.4.1. Adverse Effects of Antiviral Drugs
5.2. Market Segmentation Analysis
5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
6. Antiviral Therapeutics Market, by Drug
6.1. Introduction
6.2. Hepatitis Antiviral Drug
6.3. Herpes Antiviral Drug
6.4. HIV Antiviral Drug
6.5. Influenza Antiviral Drug
7. Antiviral Therapeutics Market, by Therapy
7.1. Introduction
7.2. DNA Polymerase Inhibitors
7.3. Neuraminidase Inhibitors
7.4. Protease Inhibitors
7.5. Reverse Transcriptase Inhibitors
8. Antiviral Therapeutics Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Independent Pharmacy & Drug Store
8.4. Online Pharmacy
9. Americas Antiviral Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antiviral Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antiviral Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
12.3.2. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
12.3.3. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIVIRAL THERAPEUTICS MARKET DYNAMICS
FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 83. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 84. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 85. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 86. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 87. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 88. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 89. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 90. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 91. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 92. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 93. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 94. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 95. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 96. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 97. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 98. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 99. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 100. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 101. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 102. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 137. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 138. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 139. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 140. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 141. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 142. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 143. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 144. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 145. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 146. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 147. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 148. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 149. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 150. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 151. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 152. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 153. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 154. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 155. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 156. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 167. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 168. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 169. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 170. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 171. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 172. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 173. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 174. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 175. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 176. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 227. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 228. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 229. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 230. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 231. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 232. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 233. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 234. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 235. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 236. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 259. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 260. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 261. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 262. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 263. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 264. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 265. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 266. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 267. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 268. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 269. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 270. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 271. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 272. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 273. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 274. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 275. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 276. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 277. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 278. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 279. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 280. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 281. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 282. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 283. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 284. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 285. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 286. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 287. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 288. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 289. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 290. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 291. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 292. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 293. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 294. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 295. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 296. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 297. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 298. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 299. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 300. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 301. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 302. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 303. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 304. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 305. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 306. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 307. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 308. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 309. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 310. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 311. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 312. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2024-2030 (USD MILLION)
TABLE 313. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 314. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
TABLE 319. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
TABLE 320. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
TABLE 321. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2023 (USD MILLION)
TABLE 322. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY,

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Atea Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Cocrystal Pharma, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 82.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 131.82 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Antiviral Drugs Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Drug Class, By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 180 Pages
  • Global
From
Antiviral Combination Therapy Global Market Report 2024 - Product Image

Antiviral Combination Therapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Hepatitis Therapeutics Market 2030 by Hepatitis Type, Drug Class, Drug Type, End-user and Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints - Product Image

Global Hepatitis Therapeutics Market 2030 by Hepatitis Type, Drug Class, Drug Type, End-user and Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints

  • Report
  • 180 Pages
  • Global
From
Antivirals Drug - Global Strategic Business Report - Product Image

Antivirals Drug - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Antivirals Global Market Report 2024 - Product Image

Antivirals Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.